Jake is the Vice President of Technology at Alchemab Therapeutics, where he leads the development of a pioneering discovery platform using AI to identify novel therapeutics. A University of Oxford PhD graduate, he previously led bioinformatics at Kymab Ltd, developing the IntelliSelect® antibody discovery platform, and is recognized as a pioneer in immune receptor repertoire sequencing.
Driven by personal experience, Jake co-founded Phylax Technologies with his brother to develop tools that support people with neurodegenerative diseases like Alzheimers. This venture aims to help prevent accidental online purchases, addressing a common challenge for those with cognitive decline and their families.
He was inspired to start Phylax after a person he knew with young-onset Alzheimers experienced difficulties with accidental online shopping.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.